

Substitute for Form 1449 A & B/PTO			Complete if Known		
			Application Number	10/564,819	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Confirmation Number	3159	
			Filing Date	January 18, 2006	
			First Named Inventor	Hiroshi OKAZAKI	
			Art Unit	1649	
			Examiner Name	Unassigned	
Sheet	1	of	6	Attorney Docket Number	Q82144

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	A1	2001/0029045	A1	10-11-2001	Rao et al.
	A2	2002/0142460	A1	10-03-2002	Rao et al.
	A3	2003/0109041	A1	06-12-2003	Rao et al.
	A4	2004/0009593	A1	01-15-2004	Keirstead et al.
	A5	2005/0101014	A1	05-12-2005	Keirstead et al.
	A6	2004/0029269	A1	02-12-2004	Goldman et al.
	A7	6,576,464	B2	06-10-2003	Gold et al.
	A8	6,235,527	B1	05-22-2001	Rao et al.
	A9	6,900,054	B2	05-31-2005	Rao et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ² (if known)			
	B1	WO	2004/011632	A2	02-05-2004	Weuss	
	B2	WO	02/088330	A2	11-07-2002	Weiss et al.	
	B3	WO	00/23571	A2	04-27-2000	Goldman et al.	
	B4	WO	97/07200	A1	02-27-1997	Barres	
	B5	WO	94/09119	A1	04-28-1994	Weiss et al.	
	B6	WO	01/28342	A1	04-26-2001	Reed	
	B7	WO	03/070171	A2	08-28-2003	Goldman et al.	
	B8	WO	03/044057	A2	05-30-2003	Lucas	
	B9	WO	03/014320	A2	02-20-2003	Goldman et al.	
	B10	CA	2322554	A1	11-26-2001	Nauw et al.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
	C1	Armstrong RC, Isolation and characterization of immature oligodendrocyte lineage cells. <i>Methods</i> 1998, 16:282-292.	
	C2	Baas D, Sarfiev LL, Ittel ME, Dussault JH, Puymirat J. Oligodendrocyte Maturation and Progenitor Cell Proliferation Are Independently Regulated by Thyroid Hormone. <i>Glia</i> 1997, 19:324-332.	
	C3	Balasubramanian V, Timmer N, Kust B, Boddeke E, Copray S. Transient expression of Olig1 initiates the differentiation of neural stem cells into oligodendrocyte progenitor cells. <i>Stem Cells</i> 2004, 22:878-882.	
	C4	Bansal R, Kumar M, Murray K, Morrison RS, Pfeiffer SE. Regulation of FGF receptors in the oligodendrocyte lineage. <i>Mol Cell Neurosci</i> 1996, 7:263-275.	
	C5	Bansal R, Pfeiffer SE. FGF-2 converts mature oligodendrocytes to a novel phenotype. <i>J Neurosci Res</i> 1997, 50:215-228.	

Examiner Signature	/Stephen Gucker/	Date Considered	08/31/2009
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the nearest "Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3)". ³For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵Applicant to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO				Complete if Known	
				Application Number	10/564,819
<u>INFORMATION DISCLOSURE</u> <u>STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				Confirmation Number	3159
				Filing Date	January 18, 2006
				First Named Inventor	Hiroshi OKAZAKI
				Art Unit	1649
				Examiner Name	Unassigned
				Attorney Docket Number	Q82144
Sheet	2	of	6		

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	6
-------	---	----	---

Complete if Known

Application Number	10/564,819
Confirmation Number	3159
Filing Date	January 18, 2006
First Named Inventor	Hiroshi OKAZAKI
Art Unit	1649
Examiner Name	<i>Unassigned</i>
Attorney Docket Number	O82144

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials ^a	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ²	Number ³	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ²
	C6	Baron W, Bansal R, Hoekstra D, de Vries H. PDGF and FGF-2 signaling in oligodendrocyte progenitor cells: regulation of proliferation and differentiation by multiple intracellular signaling pathways. <i>Mol Cell Neurosci</i> 2000, 15:314-329.	
	C7	Barres BA, Hart IK, Coles HS, Burne JF, Voyvodic JT, Richardson WD, Raff MC Cell death and control of cell survival in the oligodendrocyte lineage. <i>Cell</i> 1992, 70:31-46.	
	C8	Barres BA, Raff MC Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons. <i>Nature</i> 1993, 361:258-260.	
	C9	Barres BA, Schmid R, Sendtner M, Raff MC Multiple extracellular signals are required for long-term oligodendrocyte survival. <i>Development</i> 1993, 118:283-295.	
	C10	Besnard F, Sensenbrenner M, Labourette G. Effects of acidic and basic fibroblast growth factors on proliferation and maturation of cultured rat oligodendrocyte. <i>Int J Dev Neurosci</i> 1989, 7:401-409.	
	C11	Bogler O, Barnett SC, Land H, Noble M Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. <i>Proc Natl Acad Sci U S A</i> 1990, 87:6368-6372.	
	C12	Deloume JC, Janet T, Pettmann B, Laeng P, Knoetgen MF, Sensenbrenner M, Baudier J Phosphorylation of the MARCKS protein (P87), a major protein kinase C substrate, is not an obligatory step in the mitogenic signaling pathway of basic fibroblast growth factor in rat oligodendrocytes. <i>J Neurochem</i> 1992, 58:567-578.	
	C13	Dietrich JN, Marki M, Margot Mayer-Proschel. Characterization of A2B5 glial precursor cells from cryopreserved human fetal brain progenitor cells. <i>Glia</i> 2002, 40:65-77.	
	C14	Dubois-Dalcq M, Murray K Why are growth factors important in oligodendrocyte physiology? <i>Pathol Biol (Paris)</i> 2000, 48:80-86.	
	C15	Eccleston PA SD Fibroblast growth factor is a mitogen for oligodendrocytes in vitro. <i>Brain Res</i> 1985, 353:315-318	
	C16	Engel U, Wolswijk G Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells derived from adult rat spinal cord: in vitro characteristics and response to PDGF, bFGF and NT-3. <i>GLIA</i> 1996, 16:1-6-26.	
	C17	Fok-Seang J, Miller RH Distribution and differentiation of A2B5+ glial precursors in the developing rat spinal cord. <i>J Neurosci Res</i> 1994, 37:219-235.	
	C18	Fressinaud C SL, Labourette G. Regulation of cerebroside sulfotransferase activity in cultured oligodendrocytes: effect of growth factors and insulin. <i>J Cell Physiol</i> 1989, 141:667-674.	

Examiner Signature	/Stephen Gucker/	Date Considered	08/31/2009
--------------------	------------------	-----------------	------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (symbolical). ³ See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04, or follow the hyperlink from the title of the document to the "abstract." ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO			Complete if Known		
			Application Number	10/564,819	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Confirmation Number	3159	
			Filing Date	January 18, 2006	
			First Named Inventor	Hiroshi OKAZAKI	
			Art Unit	1649	
			Examiner Name	Unassigned	
Sheet	3	of	6	Attorney Docket Number	Q82144

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁴
		Country Code ²	Number ³	Kind Code ² (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁴
	C19	Gallo V, Paul Wright, Randall D. McKinnon Expression and regulation of a glutamate receptor subunit by bFGF in oligodendrocyte progenitors. <i>Glia</i> 1994, 10:149-153.	
	C20	Gard AL, Pfeiffer SE Glial cell mitogens bFGF and PDGF differentially regulate development of O4+GalC- oligodendrocyte progenitors. <i>Dev Biol</i> 1993, 159:618-630.	
	C21	Gard AL Two proliferative stages of the oligodendrocyte lineage (A2B5+O4- and O4+GalC-) under different mitogenic control. <i>Neuron</i> 1990, 5:615-625.	
	C22	Gard AL. Immunopanning and Developmental Stage-Specific Primary Culture of Oligodendrocyte Progenitors (O4+GalC-) Directly from Postnatal Rodent Cerebrum. <i>Neuroprotocols</i> 1993, 2:209-218.	
	C23	Gregori N, Proschel C, Noble M, Mayer-Proschel M, The Tripotential Glial-Restricted Precursor (GRP) Cell and Glial Development in the Spinal Cord: Generation of Bipotential Oligodendrocyte-Type-2 Astrocyte Progenitor Cells and Dorsal-Ventral Differences in GRP Cell Function. <i>J Neurosci</i> 2002, 22:248-256.	
	C24	Grever WE, Zhang S, Ge B, Duncan ID. Fractionation and enrichment of oligodendrocytes from developing human brain. <i>J Neurosci Res</i> 1999, 57:304-314.	
	C25	Grinspan JB, Stern JL, Franceschini B, Pleasure D Trophic effects of basic fibroblast growth factor (bFGF) on differentiated oligodendroglia: a mechanism for regeneration of the oligodendroglial lineage. <i>J Neurosci Res</i> 1993, 36:672-680.	
	C26	Grinspan JB Stage-specific effects of bone morphogenetic proteins on the oligodendrocyte lineage. <i>Journal of Neurobiology</i> 2000, 43:1-17.	
	C27	Grzenkowski M, Niehaus A, Trotter J Monoclonal antibody detects oligodendroglial cell surface protein exhibiting temporal regulation during development. <i>Glia</i> 1999, 28:128-137.	
	C28	Hoffman KL, Duncan ID Canine oligodendrocytes undergo morphological changes in response to basic fibroblast growth factor (bFGF) in vitro. <i>GLIA</i> 1995, 14:33-42.	
	C29	Ibarrola N, Mayer-Proschel M, Rodriguez-Pena A, Noble M Evidence for the existence of at least two timing mechanisms that contribute to oligodendrocyte generation in vitro. <i>Dev Biol</i> 1996, 180:1-21.	

Examiner Signature	/Stephen Gucker/	Date Considered	08/31/2009
--------------------	------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard 3). ⁴ For Japanese patent documents, the indication of the year of the region of the inventor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard 57, 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	10/564,819
		Confirmation Number	3159
		Filing Date	January 18, 2006
		First Named Inventor	Hiroshi OKAZAKI
		Art Unit	1649
Examiner Name	Unassigned		
Attorney Docket Number	Q82144		
Sheet	4	of	6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
	C30	Ingraham CA, McCarthy KD Plasticity of process-bearing glial cell cultures from neonatal rat cerebral cortical tissue. <i>J Neurosci</i> 1989, 9:63-69.	
	C31	Kessaris N, Jamen F, Rubin LI, Richardson WD Cooperation between sonic hedgehog and fibroblast growth factor/MAPK signalling pathways in neocortical precursors. <i>Development</i> 2004, 131:1289-1298.	
	C32	Kondo T, Raff M Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. <i>Science</i> 2000, 289:1754-1757.	
	C33	Lachapelle F, Avellana-Adalid V, Nait-Oumesmar B, Baron-Van Evercooren A Fibroblast growth factor-2 (FGF-2) and platelet-derived growth factor AB (PDGF AB) promote adult SVZ-derived oligodendrogenesis in vivo. <i>Mol Cell Neurosci</i> 2002, 20:390-403.	
	C34	Lillien L, Sendtner M, Raff M Extracellular matrix-associated molecules collaborate with ciliary neurotrophic factor to induce type-2 astrocyte development 10.1083/jcb.111.2.635. <i>J Cell Biol</i> 1990, 111:635-644.	
	C35	Liu S, Qu Y, Stewart TJ, Howard MJ, Chakraborty S, Holekamp TF, McDonald JW Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. <i>PNAS</i> 2000, 97:6126-6131.	
	C36	Mabie PC, Mehler MF, Marmor R, Papavasiliou A, Song Q, Kessler JA Bone morphogenetic proteins induce astroglial differentiation of oligodendroglial-astroglial progenitor cells. <i>J Neurosci</i> 1997, 17:4112-4120.	
	C37	Mason JL, Goldman JE A2B5+ and O4+ Cycling progenitors in the adult forebrain white matter respond differentially to PDGF-AA, FGF-2, and IGF-1. <i>Mol Cell Neurosci</i> 2002, 20:30-42.	
	C38	McCarthy KD, de Vellis J Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. <i>J Cell Biol</i> 1980, 85:890-902.	
	C39	McKinnon RD, Smith C, Behar T, Smith T, Dubois-Dalcq M Distinct effects of bFGF and PDGF on oligodendrocyte progenitor cells. <i>Glia</i> 1993, 7:245-254.	

Examiner Signature	/Stephen Gucker/	Date Considered	08/31/2009
--------------------	------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/564,819	
			Confirmation Number	3159	
			Filing Date	January 18, 2006	
			First Named Inventor	Hiroshi OKAZAKI	
			Art Unit	1649	
			Examiner Name	Unassigned	
			Attorney Docket Number	Q82144	
Sheet	5	of	6		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁴
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁵
	C40	McKinnon RD, Matsui T, Dubois-Daleq M, Aaronson SA. FGF modulates the PDGF-driven pathway of oligodendrocyte development. <i>Neuron</i> 1990, 5:603-614.	
	C41	Nistor G, Nadia H, Melissa K. Carpenter, and HANS S. KEIRSTEAD Human Embryonic Stem Cells Differentiate into Oligodendrocytes in High Purity and Myelinate After Spinal Cord Transplantation. <i>GLIA</i> 2005, 49:385-396.	
	C42	Noble M, The O-2A Lineage: From Rats to Humans. <i>Recent Results Cancer Res</i> 1994, 135:67-75	
	C43	Noble M, Murray K, Stroobant P, Waterfield MD, Riddle P. Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. <i>Nature</i> 1988, 333:560-562.	
	C44	Noll E, Miller R. Regulation of oligodendrocyte differentiation: a role for retinoic acid in the spinal cord. <i>Development</i> 1994, 120:649-660.	
	C45	Raff MC, Miller RH, Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. <i>Nature</i> 1983, 303:390-396.	
	C46	Rao MS, Mayer-Proschel M. Glial-restricted precursors are derived from multipotent neuroepithelial stem cells. <i>Dev Biol</i> 1997, 188:48-63.	
	C47	Saneto RP, Vellis JD. Characterization of Cultured Rat Oligodendrocytes Proliferating in a Serum-Free, Chemically Defined Medium. <i>PNAS</i> 1985, 82:3509-3513.	
	C48	Shi J, and Ben A. Barres: Purification and Characterization of Adult Oligodendrocyte Precursor Cells from the Rat Optic Nerve. <i>The Journal of Neuroscience</i> 1998, 18:4627-4636.	
	C49	Skoff R, Adelaide Stocks. Electron microscopic autoradiographic studies of gliogenesis in rat optic nerve. II. Time of origin. <i>The Journal of Comparative Neurology</i> 1976, 169:313-333.	
	C50	Tang DG, Tokumoto YM, Apperly JA, Lloyd AC, Raff MC. Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. <i>Science</i> 2001, 291:868-871.	

Examiner Signature	/Stephen Gucker/	Date Considered	08/31/2009
--------------------	------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>			<i>Complete if Known</i>	
			Application Number	10/564,819
			Confirmation Number	3159
			Filing Date	January 18, 2006
			First Named Inventor	Hiroshi OKAZAKI
			Art Unit	1649
Examiner Name			Unassigned	
Attorney Docket Number			Q82144	
Sheet	6	of	6	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ³
		Country Code ²	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁴
	C51	Tang DG, Raff MC. Long-Term Culture of Purified Postnatal Oligodendrocyte Precursor Cells: Evidence for an Intrinsic Maturation Program that Plays out over Months. <i>J Cell Biol</i> 2000, 148:971-984.	
	C52	Wilson HC, Onischke C, Raine CS. Human oligodendrocyte precursor cells in vitro: phenotypic analysis and differential response to growth factors. <i>Glia</i> 2003, 44:153-165.	
	C53	Wolszijk G, Noble M. Cooperation between PDGF and FGF converts slowly dividing O-2Aadult progenitor cells to rapidly dividing cells with characteristics of O-2Aperinatal progenitor cells 10.1083/jcb.118.4.889. <i>J Cell Biol</i> 1992, 118:889-900.	
	C54	Yim SH, Hammer JA, Quarles RII. Differences in signal transduction pathways by which platelet-derived and fibroblast growth factors activate extracellular signal-regulated kinase in differentiating oligodendrocytes. <i>J Neurochem</i> 2001, 76:1925-1934.	
	C55	Zhang SC, Ge B, Duncan ID. Tracing human oligodendroglial development in vitro. <i>J Neurosci Res</i> 2000, 59:421-429.	
	C56	Zhang SC, Lipsitz D, Duncan ID. Self-renewing canine oligodendroglial progenitor expanded as oligospheres. <i>J Neurosci Res</i> 1998, 54:181-190.	
	C57	Zhu, G. M. F. Mehler P. C. Mabie J. A. Kessler. Developmental changes in neural progenitor cell lineage commitment do not depend on epidermal growth factor receptor signaling. <i>Journal of Neuroscience Research</i> 2000, 59:312-320.	
	C58	McKinnon RD. A Role for Fibroblast Growth Factor in Oligodendrocyte Development, <i>Ann NY Acad. Sci</i> 1991, 638:378-86	

Examiner Signature	/Stephen Gucker/	Date Considered	08/31/2009
--------------------	------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. -/SG/

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlinks from the title of the document to the internet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.